Everything below concerns Thymosin fraction 5. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
=== Movement disorders === While tiapride preferentially targets the limbic system over the striatum, its moderate antagonistic effect on striatal dopamine receptors makes it effective in treating motor deficits that involve this area, such as tardive dyskinesia and chorea. Tiapride's moderate efficacy at D2 receptors may explain why it is able to treat motor symptoms without the extrapyramidal symptoms caused by excess dopamine blockage, which are sometimes seen in haloperidol or chlorpromazine. One clinical study of patients with tardive dyskinesia associated with Parkinson's disease found that tiapride significantly improved motor abilities without affecting other parkinsonian symptoms.
Butyrfentanyl or butyrylfentanyl is a potent short-acting synthetic opioid analgesic drug. It is an analog of fentanyl with around one quarter of its potency. One of the first mentions of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned as N-butyramide fentanyl analog. This document also states that the article describing its clinical effects (analgesic studies, μ-, δ-, κ-opioid receptor binding, and in vitro measures of drug efficacy, antinociceptive, and narcotic properties) was published in 1987. It is an agonist for the μ-opioid receptors. Butyrfentanyl has no current legitimate clinical applications; however, it is being sold as a designer drug. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea, and potentially serious respiratory depression which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
=== United Kingdom === A study in 2004 by the Independent Inquiry into Drug Testing at Work found that attempts by employers to force employees to take drug tests could potentially be challenged as a violation of privacy under the Human Rights Act 1998 and Article 8 of the European Convention of Human Rights. However, this does not apply to industries where drug testing is a matter of personal and public safety or security rather than productivity.
It also possible that the cells involved in these pathological states favor the reversed action of 5-HEDH, conversion of 5-oxo-ETE to 5(S)-HETE, as a consequence of reductions in oxidative stress and thereby NADP+/NADPH ratios; such cells might then actually "detoxify" 5-oxo-ETE and contribute to resolving the pathological states.
Pu-239 is produced artificially in nuclear reactors when a neutron is absorbed by U-238, forming U-239, which then decays in a rapid two-step process into Pu-239. It can then be separated from the uranium in a nuclear reprocessing plant. Weapons-grade plutonium is defined as being predominantly Pu-239, typically about 93% Pu-239. Pu-240 is produced when Pu-239 absorbs an additional neutron and fails to fission. Pu-240 and Pu-239 are not separated by reprocessing. Pu-240 has a high rate of spontaneous fission, which can cause a nuclear weapon to pre-detonate, producing a fizzle. This makes plutonium unsuitable for use in gun-type nuclear weapons. To reduce the concentration of Pu-240 in the plutonium produced, weapons program plutonium production reactors (e.g. B Reactor) irradiate the uranium for a far shorter time than is normal for a nuclear power reactor. More precisely, weapons-grade plutonium is obtained from uranium irradiated to a low burnup. This represents a fundamental difference between these two types of reactor. In a nuclear power station, high burnup is desirable. Power stations such as the obsolete British Magnox and French UNGG reactors, which were designed to produce either electricity or weapons material, were operated at low power levels with frequent fuel changes using online refuelling to produce weapons-grade plutonium. Such operation is not possible with the light water reactors most commonly used to produce electric power. In these the reactor must be shut down and the pressure vessel disassembled to gain access to the irradiated fuel.
Sources: en.wikipedia.org
== External links == "FDA revises label of diabetes drug canagliflozin". U.S. Food and Drug Administration (FDA). 15 January 2016. Archived from the original on 13 December 2019. "FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)". U.S. Food and Drug Administration (FDA). 18 May 2016. "FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate". U.S. Food and Drug Administration (FDA). 9 May 2017. Archived from the original on 1 October 2019. "Warning use metformin in certain patients with reduced kidney function". U.S. Food and Drug Administration (FDA). 14 November 2017. Archived from the original on 1 October 2019. "Warning: infection of genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 7 September 2018.
==== Organisation (1982–2018) ==== 1st Hydropower Corps - Formerly the Basic Engineering Corps 61st Detachment; Headquarters in Nanning 1st Hydropower Detachment 2nd Hydropower Detachment 3rd Hydropower Detachment Search and rescue company 4th Hydropower Detachment 5th Hydropower Detachment 2nd Hydropower Corps - Formerly the Basic Engineering Corps 63rd Detachment 7th Hydropower Detachment 8th Hydropower Detachment 9th Hydropower Detachment 3rd Hydropower Corps 10th Hydropower Detachment 12th Hydropower Detachment
=== Shape === Circulating inactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 μm in greatest diameter. Activated platelets have cell membrane projections covering their surface. In a first approximation, the shape can be considered similar to oblate spheroids, with a semiaxis ratio of 2 to 8. This approximation can be used to model the hydrodynamic and optical properties of a population, as well as to restore the geometric parameters of individual measured platelets by flow cytometry. More accurate biophysical models of platelet surface morphology that model its shape from first principles make it possible to obtain a more realistic platelet geometry in a calm and activated state.
has the effect of flattening out the distribution, similar to heating a metal. In such a distribution, it is easier to traverse between peaks (separated by valleys) than in the original distribution. After each iteration, a swap of states between two randomly chosen chains is proposed through a Metropolis-type step. Let
Sources: en.wikipedia.org
The press over the litigation and public concern over the claims of A2 Corporation led the New Zealand Food Safety Authority and the Ministry of Health and the Food Standards Australia New Zealand to issue statements confirming the safety of conventional milk. A2 Corporation was able to obtain agreements with enough dairy farmers to launch A1 protein-free milk under its a2 and a2 MILK brands in New Zealand at the end of April 2003. In the middle of 2003, both founders of the company died. In July, Paterson was found dead in his hotel room during a business trip at the age of 50, and a month later Dr Corran McLachlan died of cancer at the age of 59. In New Zealand it is illegal to make health claims about a food product without providing scientific evidence and registering the food as a medicine, and in November 2003 the New Zealand Commerce Commission advised that A2 Corporation Ltd and its licensed producers of A1 protein-free milk had agreed to amend the health claims in their promotional material following a warning from the commission. By end of 2003 the weakened A2 Corporation had withdrawn the litigation against Fonterra and negotiations had resumed. The company, which had been in a tenuous financial situation since beginning trading in May, went into administration in October and was liquidated in November, owing farmers and processors tens of thousands of dollars. A NZ$1.27 million federal government grant awarded to the company in August as part of the Regional Partnerships Program was also cancelled.
After the formation of the State Union of Serbia and Montenegro, the Yugoslav tricolour was to be replaced by a new compromise flag. Article 23 of the Law for the implementation of the Constitutional Charter stated that a law specifying the new flag was to be passed within 60 days of the first session of the new joint parliament. Among the flag proposals, the popular choice was a flag with a shade of blue in between the Serbian tricolor and the Montenegrin tricolor of 1993 through 2004. The color shade Pantone 300C was perceived as the best choice. However, the parliament failed to vote on the proposal within the legal time-frame. In 2004, Montenegro adopted a radically different flag, as its independence-leaning government sought to distance itself from Serbia. Proposals for a compromise flag were dropped after this and the Union of Serbia and Montenegro never adopted a flag. A similar fate befell the country's state anthem and coat-of-arms to be; the above-mentioned Article 23 also stipulated that a law determining the State Union's flag and anthem was to be passed by the end of 2003. The official proposal for a state anthem was a combination piece consisting of one verse of the former (now current) Serbian national anthem "Bože pravde" followed by a verse of the Montenegrin folk song, "Oj, svijetla majska zoro". This proposal was dropped after some public opposition, notably by Serbian Patriarch Pavle. Another legal deadline passed and no state anthem was adopted.
== Medical use of synthetic selenium compounds == The substance loosely called selenium sulfide (with the approximate formula SeS2) is the active ingredient in some anti-dandruff shampoos. The selenium compound kills the scalp fungus Malassezia, which causes shedding of dry skin fragments. The ingredient is also used in body lotions to treat Tinea versicolor due to infection by a different species of Malassezia fungus. Several clinical trials have assessed the use of selenium supplements in critically ill adults; however, the effectiveness and potential benefits of selenium supplementation in this context is not well understood.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.